The company board has, which met here on Saturday, approved the audited financial results for the year ended March 2000. It has confirmed the interim dividend of 50 per cent as final for the year.

The company has posted a 34.52 per cent increase in turnover at Rs 739.90 crore as against the previous year's Rs 550.03 crore. During the year under review, the company expanded its product range by introducing a wide range of cephalosporins, anti-virals, macrolides, anti-ulcerants, semi-synthetic penicillins and formations for domestic and export markets, said the company release.

On the export front, APL has reported a sales of Rs 367.35 crore as against Rs 213.46 crore in the last year, which account for over 50 per cent on the total revenue. At present, the company has presence in 70 countries, said the company.

The future focus of the company is to manufacture finished dosage formulations to cater to the regulated markets. It has set up two production facilities with an investment of Rs 30 crore, said the company sources. During the year under review, the company has set up a R&D facility at Bachupally, near Hyderabad.